JP2011507862A - 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用 - Google Patents

異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用 Download PDF

Info

Publication number
JP2011507862A
JP2011507862A JP2010539519A JP2010539519A JP2011507862A JP 2011507862 A JP2011507862 A JP 2011507862A JP 2010539519 A JP2010539519 A JP 2010539519A JP 2010539519 A JP2010539519 A JP 2010539519A JP 2011507862 A JP2011507862 A JP 2011507862A
Authority
JP
Japan
Prior art keywords
connexin
polynucleotide
scar
scars
abnormal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010539519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507862A5 (enExample
Inventor
デイビッド エル． ベッカー，
コリン アール． グリーン，
ブラッドフォード ジェイ． ダフト，
Original Assignee
コーダ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーダ セラピューティクス， インコーポレイテッド filed Critical コーダ セラピューティクス， インコーポレイテッド
Publication of JP2011507862A publication Critical patent/JP2011507862A/ja
Publication of JP2011507862A5 publication Critical patent/JP2011507862A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
JP2010539519A 2007-12-21 2008-12-22 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用 Pending JP2011507862A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US887707P 2007-12-21 2007-12-21
PCT/US2008/014028 WO2009085277A2 (en) 2007-12-21 2008-12-22 Treatment of abnormal or excessive scars

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014248308A Division JP2015057431A (ja) 2007-12-21 2014-12-08 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用

Publications (2)

Publication Number Publication Date
JP2011507862A true JP2011507862A (ja) 2011-03-10
JP2011507862A5 JP2011507862A5 (enExample) 2013-04-25

Family

ID=40824960

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010539519A Pending JP2011507862A (ja) 2007-12-21 2008-12-22 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
JP2014248308A Pending JP2015057431A (ja) 2007-12-21 2014-12-08 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014248308A Pending JP2015057431A (ja) 2007-12-21 2014-12-08 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用

Country Status (7)

Country Link
US (1) US20110130710A1 (enExample)
EP (1) EP2252690A2 (enExample)
JP (2) JP2011507862A (enExample)
AU (1) AU2008343758A1 (enExample)
CA (1) CA2710388A1 (enExample)
WO (1) WO2009085277A2 (enExample)
ZA (1) ZA201005223B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150004906A (ko) 2005-02-03 2015-01-13 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
JP2011506447A (ja) * 2007-12-11 2011-03-03 コーダ セラピューティクス， インコーポレイテッド 損傷した創傷治癒組成物および治療
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
KR102038948B1 (ko) 2012-03-01 2019-11-26 퍼스트스트링 리서치 인코포레이티드 알파 코넥신 c-말단 (act) 펩타이드를 포함하는 국소 겔
US10576037B2 (en) * 2012-03-14 2020-03-03 MAM Holdings of West Florida, L.L.C. Compositions comprising placental collagen for use in wound healing
CN104736709A (zh) 2012-03-27 2015-06-24 科达治疗公司 基于钙粘蛋白调节的组合物和治疗
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
EP4491184A3 (en) 2014-08-22 2025-03-26 Auckland Uniservices Limited Channel modulators
AU2016226415B2 (en) 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a TNF receptor 2 antagonist
WO2016149194A1 (en) 2015-03-13 2016-09-22 MAM Holdings of West Florida, L.L.C. Collagen compositions and uses for biomaterial implants
CA3061738A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
WO2019005643A1 (en) * 2017-06-26 2019-01-03 Next Science IP Holdings Pty Ltd METHOD OF TREATING PATHOLOGIES OF COLLAGEN FIBERS
WO2019152110A1 (en) * 2018-01-31 2019-08-08 Kci Usa, Inc. Antimicrobial composition, dressing, dressing components, and method
MX2023004631A (es) 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522878A (ja) * 1997-11-17 2001-11-20 ニコラス ブイー ペリコン， リポ酸を使用する瘢痕組織の治療
JP2002535377A (ja) * 1999-01-27 2002-10-22 ユニバーシテイ・カレツジ・ロンドン コネキシンに対するアンチセンスヌクレオチドを含む配合物
JP2006527234A (ja) * 2003-06-09 2006-11-30 アセンド セラピュティクス インコーポレイテッド ４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
JP2007084446A (ja) * 2005-09-20 2007-04-05 Pola Chem Ind Inc 皮膚外用剤
JP2007513148A (ja) * 2003-12-03 2007-05-24 コーダ セラピューティクス （エヌゼット） リミテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6566339B1 (en) * 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
EP1486565B1 (en) * 1995-10-11 2007-11-21 Novartis Vaccines and Diagnostics, Inc. Combination of PDGF, KGF, IGF, and IGFBP for wound healing
IT1294967B1 (it) * 1996-10-09 1999-04-23 Ist Farmacoterapico It Spa Composizione immunogenica da tlp
WO1998021358A1 (en) * 1996-11-15 1998-05-22 University Of Massachusetts Huntingtin-related therapeutics and bioassay
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
US6855505B2 (en) * 1998-06-26 2005-02-15 Renovo Limited Method for quantifying TGF-β
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US7229822B1 (en) * 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
US7186802B2 (en) * 2000-08-15 2007-03-06 Immunex Corporation Claudin polypeptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
KR20150072458A (ko) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
CA2753338A1 (en) * 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Neutral nanotransporters

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522878A (ja) * 1997-11-17 2001-11-20 ニコラス ブイー ペリコン， リポ酸を使用する瘢痕組織の治療
JP2002535377A (ja) * 1999-01-27 2002-10-22 ユニバーシテイ・カレツジ・ロンドン コネキシンに対するアンチセンスヌクレオチドを含む配合物
JP2006527234A (ja) * 2003-06-09 2006-11-30 アセンド セラピュティクス インコーポレイテッド ４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
JP2007513148A (ja) * 2003-12-03 2007-05-24 コーダ セラピューティクス （エヌゼット） リミテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
JP2007084446A (ja) * 2005-09-20 2007-04-05 Pola Chem Ind Inc 皮膚外用剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN7013002164; Ｃｕｒｒｅｎｔ　Ｂｉｏｌｏｇｙ Ｖｏｌ．１３, 2003, ｐ．１６９７-１７０３ *

Also Published As

Publication number Publication date
EP2252690A2 (en) 2010-11-24
JP2015057431A (ja) 2015-03-26
CA2710388A1 (en) 2009-07-09
ZA201005223B (en) 2011-09-28
US20110130710A1 (en) 2011-06-02
WO2009085277A3 (en) 2009-11-26
AU2008343758A1 (en) 2009-07-09
WO2009085277A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
JP2015057431A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
CN103520197B (zh) 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
US9738892B2 (en) Treatment of fibrotic conditions
JP5960944B2 (ja) 創傷治癒のための改善された方法および組成物
JP2015057430A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
JP2016135799A (ja) 損傷した創傷治癒組成物および治療
JP2015013880A (ja) 外科的癒着の治療のための抗コネキシンポリヌクレオチドの使用
JP2015083606A (ja) 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
JP2014208699A (ja) 外科的癒着の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた抗コネキシンペプチドの使用
JP2017025076A (ja) 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用
AU2015201309A1 (en) Treatment of fibrotic conditions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140807